A Huntington Memorial Hospital patient has become the first patient in
the San Gabriel Valley to be implanted with a tiny, leadless cardiac pacemaker.
Developed for patients with bradycardia – a heart rate that is too
slow – the Nanostim device is designed to be placed directly in
a patient’s heart without the visible lump, scar and insulated wires
(called leads) required for conventional pacemakers.
The implant took place last week as part of the LEADLESS II pivotal trial,
a prospective, non-randomized, multi-center, international clinical study
designed to evaluate the safety and effectiveness of the Nanostim leadless
pacemaker in patients indicated for the device in the U.S. The study is
expected to enroll approximately 670 patients at 50 centers.
The procedure was successfully performed by Huntington Hospital cardiologists
David Mok, M.D., and Director of Electrophysiology Mayer Rashtian, M.D.,
“The procedure is less invasive than traditional pacemaker surgery,
which reduces the risk of infection or other complications,” said
Dr. Mok. “Huntington is committed to continuous quality improvement
and being on the forefront of new treatments and technologies. Weare exceptionally
pleased to be part of this worldwide trial and among the first to perform
Implanted via the femoral vein with a steerable catheter, the Nanostim
leadless pacemaker offers physicians at Huntington Hospital a less-invasive
approach compared to traditional pacemaker procedures that require more
extensive surgery. The miniaturized device is designed to be fully retrievable
so that it can be readily repositioned during the implant procedure and
later retrieved if necessary.
The Nanostim leadless pacemaker is less than 10 percent the size of a conventional
pacemaker and is the least invasive pacing technology available today.
The small size of the device and lack of a surgical pocket, coupled with
the exclusion of a lead, improves patient comfort and can reduce complications,
including device pocket-related infection and lead failure. The elimination
of the visible lump and scar at a conventional pacemaker’s implant
site, in addition to the removal of patient activity restrictions that
are routinely put in place in an attempt to prevent dislodgement or damage
to a conventional lead, will potentially improve the quality of life for
patients with this technology by allowing most to continue living active,
uninhibited lifestyles. The device is supported by the St. Jude Medical
Merlin™ Programmer, which is also used to interrogate and program
the company’s other pacemakers and implantable cardioverter defibrillators (ICDs).
Cardiac pacemakers monitor the heart and provide electrical stimulation
when the heart beats too slowly for each patient's specific physiological
requirements. More than 4 million people worldwide have an implanted pacemaker
or other cardiac rhythm management device, and an additional 700,000 patients
receive the devices each year.
The Nanostim leadless pacemaker received CE Mark approval in 2013 and is
now available in select European markets. The device is not available
for sale in the U.S.
For more additional information on Nanostim pacemaker technology, visit